Soy Isoflavones and PCOS: Role in Hormonal and Metabolic Mechanisms
Source abstract
Abstract
The role of soy isoflavones, which are an example of functional food, is increasingly emphasised in the context of multiple diseases, including those related to fertility. One of the most common causes of female infertility is polycystic ovary syndrome (PCOS), which, in addition to hormonal disorders, is usually accompanied by metabolic and systemic disorders. Soy isoflavones may be helpful in treating conditions such as insulin resistance, inflammation, cardiovascular disease, and intestinal dysbiosis. The current article is a narrative review aimed at summarizing the available scientific reports on the impact of soy isoflavones on endocrine and metabolic mechanisms in women with PCOS. Despite the limitations, current scientific evidence suggests that soy isoflavones can significantly contribute to lowering metabolic risk and affect hormonal balance in women with PCOS. Promising results have come from studies on PCOS and the gut microbiota, where a bidirectional relationship is suggested: the influence of the gut microbiota on the bioavailability of soy isoflavones and the modulation of microbiota composition by these compounds. However, further interventional studies involving humans are needed to better understand the endocrine and metabolic relationships regarding the role and importance of soy isoflavones in the pathomechanisms of the development and treatment of these disorders.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ovarian function and disorders · Phytoestrogen effects and research · Reproductive Biology and Fertility
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Health Sciences and Psychology, University of Rzeszów, 35-959 Rzeszów, Poland
References (100+)
Show source-provided references
1. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome10.1210/clinem/dgad463 ↗
2. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome10.1093/humrep/dey256 ↗
3. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline10.1210/jc.2006-0178 ↗
4. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis10.1093/humrep/dew218 ↗
5. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria10.1093/humrep/dep399 ↗
6. Food sources of phyto-oestrogens and their precursors in Europe10.1079/BJN2002795 ↗
7. Křížová, L., Dadáková, K., Kašparovská, J., and Kašparovský, T. (2019). Isoflavones. Molecules, 24.10.3390/molecules24061076 ↗
8. Determinants of ligand specificity of estrogen receptor-alpha: Estrogen versus androgen discrimination10.1074/jbc.273.2.693 ↗
9. Therapeutic potential of selective estrogen receptor modulators10.1016/S1367-5931(98)80127-0 ↗
10. Mammalian phytoestrogens: Enterodiol and enterolactone10.1016/S1570-0232(02)00281-7 ↗
11. The soy isoflavone genistein induces estrogen synthesis in an extragonadal pathway10.1016/j.mce.2009.01.003 ↗
12. Acute and chronic effects of genistein, tyrphostin and lavendustin A on steroid synthesis in luteinized human granulosa cells10.1093/humrep/17.3.589 ↗
13. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study10.1289/ehp.9810685 ↗
14. The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome10.1210/jc.2016-1762 ↗
15. Effect of soy phytoestrogen on metabolic and hormonal disturbance of women with polycystic ovary syndrome
16. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study10.1016/j.fertnstert.2007.09.020 ↗
17. Haudum, C., Lindheim, L., Ascani, A., Trummer, C., Horvath, A., Münzker, J., and Obermayer-Pietsch, B. (2020). Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics. Nutrients, 12.10.3390/nu12061622 ↗
18. Soy, soy isoflavones, and protein intake in relation to mortality from all causes, cancers, and cardiovascular diseases: A systematic review and dose-response meta-analysis of prospective cohort studies10.1016/j.jand.2019.04.011 ↗
19. Soy and isoflavone consumption and multiple health outcomes: Umbrella review of systematic reviews and meta-analyses of observational studies and randomized trials in humans10.1002/mnfr.201900751 ↗
20. Soy intake is associated with lowering blood pressure in adults: A systematic review and meta-analysis of randomized double-blind placebo-controlled trials10.1016/j.ctim.2021.102692 ↗
21. Effect of soy isoflavones on blood pressure: A meta-analysis of randomized controlled trials10.1016/j.numecd.2010.09.006 ↗
22. Consumption of soy foods and isoflavones and risk of type 2 diabetes: A pooled analysis of three US cohorts10.1038/ejcn.2016.117 ↗
23. Rizzo, G. (2020). The Antioxidant Role of Soy and Soy Foods in Human Health. Antioxidants, 9.10.3390/antiox9070635 ↗
24. From Gut to Hormones: Unraveling the Role of Gut Microbiota in (Phyto)Estrogen Modulation in Health and Disease10.1002/mnfr.202300688 ↗
25. Meta-analysis of gut microbiota biodiversity in patients with polycystic ovary syndrome based on medical images10.1016/j.slast.2024.100178 ↗
26. Lindheim, L., Bashir, M., Munzker, J., Trummer, C., Zachhuber, V., Leber, B., Horvath, A., Pieber, T.R., Gorkiewicz, G., and Stadlbauer, V. (2017). Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. PLoS ONE, 12.10.1371/journal.pone.0168390 ↗
27. The gut microbial composition in polycystic ovary syndrome with insulin resistance: Findings from a normal-weight population10.1186/s13048-021-00799-9 ↗
28. Goh, Y.X., Jalil, J., Lam, K.W., Husain, K., and Premakumar, C.M. (2022). Genistein: A review on its anti-inflammatory properties. Front. Pharmacol., 13.10.3389/fphar.2022.820969 ↗
29. Mei, J., Chen, X., Liu, J., Yi, Y., Zhang, Y., and Ying, G. (2019). A biotransformation process for production of genistein from sophoricoside by a strain of Rhizopus oryza. Sci. Rep., 9.10.1038/s41598-019-42996-z ↗
30. Daidzein and genistein content of fruits and nuts10.1016/S0955-2863(00)00085-1 ↗
31. Effects of phytoestrogens on reproductive organ health10.1007/s12272-022-01417-y ↗
32. Quantification of genistein and genistin in soybeans and soybean products10.1016/0278-6915(96)87355-8 ↗
33. Isoflavonoid glucosides are deconjugated and absorbed in the small intestine of human subjects with ileostomies10.1093/ajcn/85.4.1050 ↗
34. Study on biotransformation and absorption of genistin based on fecal microbiota and Caco-2 cell10.3389/fphar.2024.1437020 ↗
35. Daidzein and genestein contents in tempeh and selected soy products10.1016/j.foodchem.2009.01.053 ↗
36. Garbiec, E., Cielecka-Piontek, J., Kowalówka, M., Hołubiec, M., and Zalewski, P. (2022). Genistein—Opportunities Related to an Interesting Molecule of Natural Origin. Molecules, 27.10.3390/molecules27030815 ↗
37. Bioavailability and pharmacokinetics of genistein: Mechanistic studies on its ADME10.2174/187152012803833107 ↗
38. Yu, L., Rios, E., Castro, L., Liu, J., Yan, Y., and Dixon, D. (2021). Genistein: Dual Role in Women’s Health. Nutrients, 13.10.3390/nu13093048 ↗
39. Solubility of Genistein in Water, Methanol, Ethanol, Pro-pan-2-ol, 1-Butanol, and Ethyl Acetate from (280 to 333) K10.1021/je100261w ↗
40. Transport mechanisms of soy isoflavones and their microbial metabolites dihydrogenistein and dihydrodaidzein across monolayers and membranes
41. Bacterial species involved in the conversion of dietary flavonoids in the human gut10.1080/19490976.2016.1158395 ↗
42. Dihydrogenistein-producing bacterium TM-40 isolated from human feces10.3136/fstr.13.129 ↗
43. Analysis of Soy Isoflavone Conjugation In Vitro and in Human Blood Using Liquid Chromatography-Mass Spectrometry10.1016/S0090-9556(24)15365-2 ↗
44. Effects of isoflavones on breast tissue and the thyroid hormone system in humans: A comprehensive safety evaluation10.1007/s00204-018-2279-8 ↗
45. Receptor binding and transactivation activities of red clover isoflavones and their metabolites10.1016/j.jsbmb.2008.08.007 ↗
46. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women10.1093/jn/124.6.825 ↗
47. Guelfi, G., Pasquariello, R., Anipchenko, P., Capaccia, C., Pennarossa, G., Brevini, T.A.L., Gandolfi, F., Zerani, M., and Maranesi, M. (2023). The Role of Genistein in Mammalian Reproduction. Molecules, 28.10.3390/molecules28217436 ↗
48. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta10.1210/endo.138.3.4979 ↗
49. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta10.1210/endo.139.10.6216 ↗
50. Genistein Combined with FOLFOX or FOLFOX–Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study10.1007/s00280-019-03886-3 ↗
51. Koenig, A., Buskiewicz, I., and Huber, S.A. (2017). Age-Associated changes in estrogen receptor ratios correlate with increased female susceptibility to Coxsackievirus B3-Induced myocarditis. Front. Immunol., 8.10.3389/fimmu.2017.01585 ↗
52. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis10.1095/biolreprod.107.061804 ↗
53. Abbasi, S. (2010). Estrogen Receptor-Beta Gene Polymorphism in women with Breast Cancer at the Imam Khomeini Hospital Complex, Iran. BMC Med. Genet., 11.10.1186/1471-2350-11-109 ↗
54. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids10.1677/joe.0.1470295 ↗
55. Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection10.1016/j.exppara.2018.01.013 ↗
56. Modulation of Adipocyte Differentiation and Proadipogenic Gene Expression by Sulforaphane, Genistein, and Docosahexaenoic Acid as a First Step to Counteract Obesity10.1155/2018/1617202 ↗
57. Lv, Z., Xing, K., Li, G., Liu, D., and Guo, Y. (2018). Dietary Genistein Alleviates Lipid Metabolism Disorder and Inflammatory Response in Laying Hens with Fatty Liver Syndrome. Front. Physiol., 9.10.3389/fphys.2018.01493 ↗
58. Genistein directly inhibits GLUT4-mediated glucose uptake in 3T3-L1 adipocytes10.1016/j.bbrc.2004.11.055 ↗
59. Genistein Is a Natural Inhibitor of Hexose and Dehydroascorbic Acid Transport through the Glucose Transporter, GLUT110.1074/jbc.271.15.8719 ↗
60. Complementary and alternative medicine for menopause10.1177/2515690X19829380 ↗
61. Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone10.1002/ptr.7852 ↗
62. Bhagwat, S., Hayowitz, D.B., and Holden, J.M. (2008). USDA Database for the Isoflavone Content of Selected Foods, Release 2.0.
63. Singh, S., Grewal, S., Sharma, N., Behl, T., Gupta, S., Anwer, M.K., Vargas-De-La-Cruz, C., Mohan, S., Bungau, S.G., and Bumbu, A. (2023). Unveiling the Pharmacological and Nanotechnological Facets of Daidzein: Present State-of-the-Art and Future Perspectives. Molecules, 28.10.3390/molecules28041765 ↗
64. Daidzein is absorbed by passive transport in isolated small intestine of rats10.1016/j.nutres.2006.06.005 ↗
65. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity10.1016/S0014-5793(98)01101-6 ↗
66. Sirotkin, A.V., Alwasel, S.H., and Harrath, A.H. (2021). The Influence of Plant Isoflavones Daidzein and Equol on Female Reproductive Processes. Pharmaceuticals, 14.10.3390/ph14040373 ↗
67. Mayo, B., Vázquez, L., and Flórez, A.B. (2019). Equol: A Bacterial Metabolite from The Daidzein Isoflavone and Its Presumed Beneficial Health Effects. Nutrients, 11.10.3390/nu11092231 ↗
68. Production of equol, dehydroequol, 5-hydroxy-equol and 5-hydroxy-dehydroequol in soy beverages by the action of dihydrodaidzein reductase in Limosilactobacillus fermentum strains10.1016/j.foodchem.2024.141707 ↗
69. The antioxidant activity of daidzein metabolites, O-desmethylangolensin and equol, in HepG2 cells10.3892/mmr.2013.1752 ↗
70. Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of R-and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta10.1016/j.bmc.2003.11.035 ↗
71. Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls10.1093/jn/136.5.1347 ↗
72. Method of defining equol-producer status and its frequency among vegetarians10.1093/jn/136.8.2188 ↗
73. Dietary factors influence production of the soy isoflavone metabolite S-(-)equol in healthy adults10.3945/jn.113.179564 ↗
74. Effect of S-equol and Soy Isoflavones on Heart and Brain10.2174/1573403X15666181205104717 ↗
75. Estrogenic and genotoxic potential of equol and two hydroxylated metabolites of daidzein in cultured human Ishikawa cells10.1016/j.toxlet.2005.02.011 ↗
76. Xu, X.-L., Deng, S.-L., Lian, Z.-X., and Yu, K. (2021). Estrogen Receptors in Polycystic Ovary Syndrome. Cells, 10.10.3390/cells10020459 ↗
77. Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks10.1002/mnfr.201200439 ↗
78. Suppression of isoproterenol-induced apoptosis in H9c2 cardiomyoblast cells by daidzein through activation of Akt10.4077/CJP.2016.BAE393 ↗
79. Is soy consumption good or bad for the breast?10.3945/jn.110.124230 ↗
80. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome10.1093/humupd/dml036 ↗
81. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
82. Women with Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: A Population Study10.1210/clinem/dgab392 ↗
83. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome10.1210/jc.2004-1045 ↗
84. Polycystic ovary syndrome: A biopsychosocial understanding in young women to improve knowledge and treatment options10.3109/01674820903477593 ↗
85. Is having polycystic ovary syndrome (PCOS) a predictor of poor psychological function including depression and anxiety10.1093/humrep/der071 ↗
86. Teede, H., Deeks, A., and Moran, L. (2010). Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med., 8.10.1186/1741-7015-8-41 ↗
87. Dermatologic manifestations of polycystic ovary syndrome10.2165/00128071-200708040-00003 ↗
88. Polycystic ovary syndrome: A review for dermatologists: Part I. Diagnosis and manifestations10.1016/j.jaad.2014.05.007 ↗
89. Diagnosis of Polycystic Ovary Syndrome: Which Criteria to Use and When?10.1016/j.ecl.2020.10.002 ↗
90. ESE PCOS Special Interest Group. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology10.1530/EJE-14-0253 ↗
91. Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause10.1210/jc.2013-2375 ↗
92. Polycystic ovary syndrome: A multifaceted disease from adolescence to adult age10.1196/annals.1365.014 ↗
93. Resumption of ovulation in anovulatory women with PCOS and obesity is associated with reduction of 11β-hydroxyandrostenedione concentrations10.1093/humrep/deae058 ↗
94. Gautam, R., Maan, P., Jyoti, A., and Kumar, A. (2025). The Role of Lifestyle Interventions in PCOS Management: A Systematic Review. Nutrients, 17.10.3390/nu17020310 ↗
95. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited10.1210/er.2015-1104 ↗
96. Higher dietary inflammation potential and certain dietary patterns are associated with polycystic ovary syndrome risk in China: A case-control study10.1016/j.nutres.2021.12.006 ↗
97. Zeber-Lubecka, N., Ciebiera, M., and Hennig, E.E. (2023). Polycystic Ovary Syndrome and Oxidative Stress-From Bench to Bedside. Int. J. Mol. Sci., 24.10.3390/ijms241814126 ↗
98. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers10.1155/2016/8589318 ↗
99. The effects of portfolio moderate-carbohydrate and ketogenic diets on anthropometric indices, metabolic status, and hormonal levels in overweight or obese women with polycystic ovary syndrome: A randomized controlled trial10.1186/s12937-024-01056-7 ↗
100. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake10.1016/j.cmet.2019.05.020 ↗